Telehealth

Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. The platforms compared in this article are operating telehealth services that connect patients with licensed clinicians for compounded GLP-1 medication evaluation. Compounded GLP-1 medications are not FDA-approved finished drugs. Nothing in this article constitutes medical advice. Pricing referenced reflects each platform's published rates as of the review date.

The compounded-GLP-1 telehealth category has compressed pricing rapidly over the past eighteen months. Three platforms occupy the value end of the market that most patients evaluate: Oak Longevity, Mochi Health, and Hims. Each markets aggressively on price. Each presents the price differently. Patients comparing them on the marketing copy alone will not arrive at the right answer for their specific situation. This comparison takes the published pricing structures, normalizes them to total monthly out-of-pocket cost, and identifies which platform actually wins on cost — and where each platform fits clinically beyond the cost question.

Headline Pricing — What Each Platform Publishes

Oak Longevity publishes compounded semaglutide from $130 per month and compounded tirzepatide from $199 per month, with no separate membership fee, free shipping, and free health coaching included. The platform offers $50 off the first month with promotional code OAKNEW50.

Mochi Health publishes a $79 per month membership fee that includes provider visits, registered dietitian access, and care coordination, plus a separate $99 per month for compounded semaglutide or $199 per month for compounded tirzepatide at every dose. Total monthly out-of-pocket cost on Mochi semaglutide is therefore $178 per month, and Mochi tirzepatide is $278 per month.

Hims publishes compounded semaglutide injectable plans starting at $199 per month with a six-month prepayment commitment (approximately $1,194 upfront), and oral kit options starting at $69 per month with a ten-month prepayment commitment (approximately $690 upfront). The headline $69 per month figure refers to non-GLP-1 oral kit combinations rather than the GLP-1 active ingredient itself; the GLP-1 injectable pricing on Hims starts at $199 per month with prepay.

Total Monthly Cost — Normalized

Comparing on a single month, no prepayment, compounded semaglutide basis: Oak Longevity at $130 is the lowest. Mochi Health at $178 total is second. Hims at $199 with a six-month prepayment commitment is third by per-month figure but requires the most upfront capital.

Comparing on annualized cost at the published starting prices, semaglutide only: Oak at approximately $1,560 per year. Mochi at approximately $2,136 per year. Hims at approximately $2,388 per year on the six-month prepay structure. The difference between Oak and Mochi over a year — roughly $576 — is meaningful for patients on long-term GLP-1 therapy.

For tirzepatide, the gap narrows. Oak Longevity from $199 per month is approximately $2,388 per year. Mochi at $79 + $199 = $278 per month is approximately $3,336 per year. The Oak-to-Mochi annual gap on tirzepatide is approximately $948 — even larger in absolute dollars, though smaller as a percentage.

One critical caveat applies across all three platforms: these are starting or flat-rate published prices. Across the compounded-GLP-1 telehealth category, dose-specific pricing varies. Patients should confirm during the consultation whether the headline price applies at every titration step, particularly as patients move from initial low doses to clinically effective maintenance doses. This is a question worth asking on every platform, not just Oak. We covered the dose-titration consideration in detail in our Oak Longevity review.

Intake and Clinical Depth

Cost is one variable. Clinical fit is another. The three platforms differ meaningfully on how the clinical relationship is structured.

Oak Longevity uses an asynchronous intake — an online health questionnaire reviewed by a licensed provider, with no scheduled video visit required for initial evaluation. This is the fastest intake of the three and works well for patients with straightforward weight-management goals and no significant comorbid complexity. Patients can typically progress from intake to prescription approval within hours.

Mochi Health emphasizes live video visits with a board-certified obesity medicine physician or nurse practitioner, plus access to a registered dietitian for nutrition coaching. Mochi's care model is the most clinically intensive of the three. The cost — $79 per month membership for what would otherwise be billed as multiple separate visits and consultations — accounts for that depth. Patients with multiple comorbidities, complex weight histories, or those who want a registered dietitian's involvement will find Mochi's structure better suited even at the higher price.

Hims operates predominantly asynchronously, similar to Oak, but with structured follow-up check-ins built into the multi-month prepayment plan. The Hims clinical experience sits within a broader men's-health ecosystem rather than a dedicated obesity medicine specialty, though its providers are licensed clinicians who prescribe within state regulations.

Formulary Breadth

Patients who want only compounded semaglutide or compounded tirzepatide will find adequate access on all three platforms. The differences emerge when other options are needed.

Mochi Health offers the broadest formulary in the category, including FDA-approved brand-name medications when clinically appropriate (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, Rybelsus), oral semaglutide tablets (the FDA-approved Rybelsus pathway), and non-GLP-1 alternatives (metformin, topiramate, naltrexone, bupropion, orlistat). Mochi also operates a pediatric-eligible weight-management program for patients under 18 with appropriate clinical criteria, which neither Oak nor Hims publishes.

Hims offers brand-name medications alongside compounded semaglutide and several oral kit combinations that include non-GLP-1 active ingredients. The Hims formulary is narrower than Mochi's but broader than Oak's.

Oak Longevity's formulary is compounded-focused, primarily compounded semaglutide and compounded tirzepatide. Patients seeking FDA-approved brand-name medications, oral GLP-1 tablets, or non-GLP-1 alternatives should confirm availability with Oak directly during the intake or evaluate a platform with broader documented options. For more on what compounded versus brand-name actually means for cost and outcomes, see our Compounded Semaglutide Cost analysis.

Brand-Name FDA-Approved Access

This is where the platforms diverge most sharply. Patients who specifically want — or whose clinical situation requires — an FDA-approved brand-name GLP-1 medication should plan accordingly.

Mochi Health and Hims both offer documented pathways to FDA-approved Wegovy, Ozempic, Mounjaro, and Zepbound when clinically appropriate. Brand-name medications cost substantially more out-of-pocket — typically several hundred to over a thousand dollars per month without insurance coverage — but represent the medications studied in the peer-reviewed STEP and SURMOUNT trials.

Oak Longevity's published platform is compounded-focused. The on-domain SynergyRx review covers a platform with broader brand-name access at higher prices. We covered SynergyRx's pricing structure for brand-name medications in our SynergyRx review, where Wegovy and Mounjaro start at approximately $947 per month and Ozempic starts at approximately $499 per month.

Cancellation and Commitment

Oak Longevity advertises “no subscriptions” and bills month-to-month based on the published platform information. Patients can stop ordering refills without committing to a fixed-duration contract. This flexibility has real value for patients uncertain whether GLP-1 therapy will fit their life long-term.

Mochi Health offers monthly billing as the default, plus 3-month and 12-month prepayment options that reduce the monthly figure by roughly $40. Cancellation is straightforward but requires actively cancelling both the membership and the medication subscription separately — a structure that has produced significant complaint volume in consumer review databases.

Hims requires multi-month prepayment commitments for the headline pricing tiers. The six-month prepay for injectable semaglutide and the ten-month prepay for oral kits both involve substantial upfront capital. Patients who change their mind during the prepayment period face refund navigation.

Side Effect Support

One operational detail that does not show up in pricing comparisons: whether the platform offers prescription anti-nausea medication access. Nausea is the most common side effect of GLP-1 initiation and titration. Some platforms include ondansetron or similar prescription support when clinically appropriate; others do not.

Mochi Health publishes ondansetron access as part of the supportive care framework. Hims' broader pharmacy network includes anti-nausea options. Oak Longevity, based on Trustpilot user reports, has been noted as not currently offering prescription anti-nausea support alongside the GLP-1 prescription. Patients prone to nausea or with prior GLP-1 nausea history may want to confirm this availability with Oak directly or weight it as a factor in platform choice.

Who Each Platform Fits Best

Oak Longevity fits patients who want the lowest published starting price for compounded semaglutide on a no-membership-fee, no-prepayment basis, who are comfortable with asynchronous intake, and whose clinical situation is straightforward. The single-figure monthly price is the cleanest in the category.

Mochi Health fits patients who value live video provider access, registered dietitian involvement, broad formulary including brand-name and non-GLP-1 alternatives, and structured ongoing clinical care, and who can absorb the higher monthly total cost in exchange for that clinical depth.

Hims fits patients who can commit to multi-month prepayment, want access to both compounded and brand-name medications, and prefer the integration of weight management within a broader men's-health platform context.

The Honest Read

Oak Longevity wins the published-starting-price comparison on a no-commitment basis. That is real. It is also a starting price, and what any specific patient pays at maintenance dose depends on questions that must be answered during the consultation, not from a comparison table.

Mochi Health is more expensive monthly but delivers a more clinically intensive program with a broader formulary. For patients whose clinical situation benefits from that depth, the price differential is the right tradeoff. For patients with simpler situations, it is overpaying for unused capacity.

Hims is the highest barrier to entry due to prepayment requirements and is the most ecosystem-integrated platform of the three. Patients who already use Hims for other men's-health services may find the integration valuable; patients evaluating purely on weight-management terms will find better fit elsewhere.

For deeper coverage of the compounded GLP-1 telehealth category, see our Telehealth Platform Reviews hub. For evidence-based weight management beyond pharmaceutical interventions, see our Weight Management coverage. The clinical decision to use any GLP-1 medication, compounded or brand-name, belongs to the patient and a licensed healthcare provider.

Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs. Pricing referenced reflects each platform's published rates as of the review date and is subject to change.

Important: Both MadeMed and MEDVi facilitate access to compounded prescription medications that are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This comparison is for educational purposes only. Consult a licensed healthcare provider before starting any prescription treatment. Pricing is subject to change — verify current terms directly on each platform's official website before enrolling.

If you've been researching compounded GLP-1 telehealth programs, you've almost certainly encountered both MadeMed and MEDVi. They're two of the more visible platforms in the current market, they offer overlapping medication formats, and they're both frequently appearing in the same search results. What they don't offer is a side-by-side comparison written by someone who has actually read both platforms' terms, sourced verified pricing, and documented the meaningful differences. That's what this article does.

Company Overview: What Each Platform Is

MadeMed is operated by IDL Health LLC, headquartered in Houston, Texas. Medical services are provided by Xpedicare, LLC, an independent medical group whose licensed clinicians make all prescribing decisions. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner. MadeMed holds LegitScript certification. As of available verified sources, no FDA warning letters have been identified for MadeMed as of the date of this review.

MEDVi is a telehealth platform that has been operating since 2023 and is based in Newark, Delaware. Prescriptions are overseen by board-certified U.S. physicians through the OpenLoop Health provider network. Medication is dispensed through Belmar Pharma Solutions, a licensed compounding pharmacy operating since 1985 and accredited by NABP across all its locations. MEDVi holds LegitScript certification and reports serving over 100,000 patients. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language the FDA found implied FDA approval and suggested MEDVi was the compounder of the medications it sold. The letter did not allege contaminated or improperly manufactured medications. For our full independent review of MEDVi's platform, see our MEDVi GLP-1 program review.

Verified Pricing Comparison: What Each Platform Actually Charges

The pricing figures below are drawn from publicly available sources verified as of April to May 2026. All prices represent published starting doses. Dose increases typically increase cost. Verify current pricing directly on each platform before enrolling.

Injectable Semaglutide: MadeMed lists $179 per month at the starting dose (0.25mg), inclusive of L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) reduces this by $10 per month. MEDVi lists $179 for the first month as an introductory rate, then $299 per month for ongoing refills. MEDVi charges no separate membership fee.

Oral Semaglutide (sublingual): MadeMed lists $169 per month at the starting dose (1mg), with 30 sublingual tablets. MadeMed Club reduces this by $10 per month. MEDVi lists oral semaglutide tablets starting at $249 for the first month, then $369 per month ongoing. At every dose tier in available verified data, MadeMed's published oral semaglutide price is lower than MEDVi's.

Injectable Tirzepatide: MadeMed lists $189 per month at the starting dose (2.5mg), inclusive of the same supplies package as semaglutide. MadeMed Club reduces this by $20 per month. MEDVi lists injectable tirzepatide starting at $279 for the first month, then $399 per month ongoing.

Oral Tirzepatide (sublingual): Neither platform has a confirmed published starting price for oral tirzepatide in independently verified sources as of this writing. MEDVi's ongoing rate for compounded tirzepatide (injectable and oral combined into one tier) is reported at $399 per month. Verify oral tirzepatide pricing and current availability directly on each platform. Note: as of January 2026, there is no FDA-approved oral tirzepatide product in any format. Oral tirzepatide from telehealth platforms is a compounded sublingual formulation that has not been evaluated by the FDA.

One structural pricing difference worth understanding: MEDVi bills on a 28-day cycle rather than a calendar month, producing 13 billing events per year rather than 12. At $299 per month for semaglutide, the annual cost is approximately $3,887 — not $3,588 as a 12-month calculation would suggest. MadeMed's billing cycle structure (30-day vs. 90-day subscription options) should be verified directly on the platform.

What's Included: The Bundling Difference

MadeMed explicitly states that its injectable programs include L-Carnitine, physician consultation, overnight shipping, and injection supplies in the listed monthly price. For patients who would otherwise pay separately for these items, the all-in pricing model simplifies cost comparison. MEDVi's pricing includes provider consultation and medication; verify current shipping and supply terms directly on MEDVi's platform, as bundling structures in the telehealth market can change.

The MadeMed Club membership ($149/year) provides monthly discounts of $10 on semaglutide programs and $20 on tirzepatide programs. At the tirzepatide discount rate, the membership pays for itself in approximately 7.5 months. For patients planning a sustained treatment course, the math favors joining. For patients uncertain about long-term commitment, the month-to-month standard pricing avoids the upfront membership cost.

Medication Range: Where the Platforms Diverge

For GLP-1 programs specifically, both platforms offer the same four core formats: injectable semaglutide, oral sublingual semaglutide, injectable tirzepatide, and oral sublingual tirzepatide. MEDVi additionally offers access to brand-name Wegovy and Ozempic at premium pricing tiers for patients who specifically require FDA-approved finished drug products — an option MadeMed does not appear to offer, according to available verified sources.

MadeMed's range extends beyond GLP-1 into categories MEDVi doesn't cover: sermorelin-based peptide therapy in injectable and oral formats, a tadalafil/PT-141/oxytocin men's wellness troche, and NAD+ therapy in injectable and nasal spray formats. For patients whose clinical needs include any of these categories, in addition to weight management, MadeMed offers a single-platform model that MEDVi doesn't match. For our detailed breakdown of MadeMed's peptide and NAD+ programs, see our MadeMed sermorelin and peptide therapy review.

Regulatory History: What the Record Shows

This section matters more in 2026 than it would have in prior years, given the FDA's escalated enforcement posture in the compounded GLP-1 market since September 2025.

MEDVi received a formal FDA warning letter in February 2026. The letter cited misbranding violations specifically — marketing language the agency found implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. MEDVi holds active LegitScript certification as of the publication date of this review, and the warning letter did not allege medication contamination or manufacturing deficiencies. Warning letters require a response and corrective action; they do not automatically result in enforcement action or platform shutdown. But they are on the public record, and patients evaluating platforms should know they exist.

No FDA warning letters have been identified for MadeMed in available verified sources as of this writing. This is not a guarantee of future regulatory status — the compounded GLP-1 market remains under active FDA scrutiny, and conditions for all platforms in this space continue to evolve.

Patient Review Volume and Signals

MEDVi has a substantially larger public review footprint: over 10,000 Trustpilot reviews with a 4.4 to 4.5 star average as of early 2026. Common praise focuses on fast approval, clinical team responsiveness, and accessible provider messaging. Common complaints cluster around billing practices and subscription management — a pattern typical of telehealth platforms using auto-renewal subscription models, not a signal specific to clinical quality.

MadeMed has a smaller public review volume, consistent with its relative market age. A smaller review footprint does not indicate lower quality — it reflects how recently a platform entered the market and how aggressively it has solicited public reviews. Evaluate review signals as one data point among several, not as a primary decision factor.

State Availability

MEDVi reports availability in 49 states (North Dakota excluded as of early 2026 data). MadeMed reports availability in approximately 40 states. If your state's availability is a deciding factor, verify both platforms' current service areas directly — state-level availability in the telehealth GLP-1 market changes as platforms adjust to evolving state telehealth regulations.

How to Choose Between Them

If your primary goal is compounded GLP-1 for weight management and you want the lowest published starting price across semaglutide formats, MadeMed's published pricing is lower at every tier in the verified data. If you want access to brand-name FDA-approved GLP-1 options through the same platform, MEDVi offers that and MadeMed does not appear to. If you need peptide therapy or NAD+ alongside a GLP-1 program, MadeMed is the single-platform option. If you want the largest available patient review base as a signal before committing, MEDVi's review volume is substantially larger. If FDA warning letter history factors into your evaluation, MEDVi has one on record from February 2026 and MadeMed does not.

Neither of these is a definitive answer about which platform is better for any individual patient. The right platform is the one whose clinical team, after reviewing your specific health history, determines an appropriate treatment path for you. Both platforms use licensed clinicians for that determination. Both use licensed pharmacy partners for dispensing. Both operate under the same compounded medication regulatory framework. The differences are in pricing structure, medication range, regulatory history, and review volume — all of which are factors you can evaluate before completing an intake form. For our full breakdowns, see the complete MadeMed review and the complete MEDVi review.

Frequently Asked Questions

Is MadeMed or MEDVi cheaper for injectable semaglutide?

Based on published April 2026 pricing, MadeMed lists injectable semaglutide at $179 per month — identical to MEDVi's introductory first-month rate. MEDVi's ongoing monthly rate after the first month rises to $299. MadeMed's published pricing does not clearly distinguish between an introductory and an ongoing rate in the available verified sources; verify current tier pricing directly on each platform before enrolling.

Did MEDVi receive an FDA warning letter?

Yes. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language that implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. The letter did not allege that the medications were contaminated or improperly manufactured. MEDVi holds an active LegitScript certification as of the publication date of this review.

Which platform offers more medication formats?

Both platforms offer compounded semaglutide and tirzepatide in injectable and sublingual oral formats. MadeMed additionally offers sermorelin peptide therapy (injectable and oral) and NAD+ therapy (injectable and nasal spray). MEDVi offers brand-name Wegovy and Ozempic at premium pricing tiers. The right platform depends on which medications and categories are relevant to your individual situation.

Which platform has more patient reviews?

MEDVi has a substantially larger public review footprint, with over 10,000 Trustpilot reviews and an average rating of 4.4 to 4.5 as of early 2026. MEDVi has been operating since 2023 and reports serving over 100,000 patients. MadeMed has a smaller public review volume reflecting its relative market age. Review volume and scores are useful signals, but should not be the sole basis for a prescribing decision.

Important: Sermorelin and other peptide therapies discussed in this article are prescription medications. Compounded formulations are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational purposes only. Consult your licensed healthcare provider before starting any prescription peptide therapy.

Most coverage of MadeMed focuses on its GLP-1 weight-loss programs, which makes sense — that's where patient volume and search interest are highest. But MadeMed also offers sermorelin-based peptide therapy in both injectable and oral formats, and that category deserves the same research-depth treatment this site applies to every telehealth program we review. This article covers what sermorelin is, what the clinical evidence actually supports, how MadeMed's peptide programs are structured, and the regulatory context you need to understand before enrolling.

What Is Sermorelin?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone, or GHRH. Rather than introducing exogenous growth hormone directly — as growth hormone replacement therapy does — sermorelin stimulates the pituitary gland to produce and release growth hormone via the body's natural regulatory feedback mechanisms. This distinction matters clinically. Because sermorelin operates upstream of growth hormone production rather than bypassing the regulatory system entirely, it preserves the pituitary's own feedback controls to a greater degree than direct growth hormone administration.

Sermorelin was previously FDA-approved under the name Geref for the evaluation and treatment of growth hormone deficiency in children. That approval was voluntarily withdrawn by the manufacturer — not due to a safety finding, but for commercial reasons. Sermorelin prescribed through telehealth platforms today is compounded, meaning it is formulated by a licensed compounding pharmacy for specific patients and is not an FDA-approved finished drug product.

What the Research Supports — and What It Doesn't

The evidence base for sermorelin is meaningful but narrower than its marketing footprint might suggest. Published research has examined sermorelin's effects on growth hormone secretion, IGF-1 levels, body composition, and sleep quality in specific populations, primarily adults with documented growth hormone deficiency or age-related growth hormone decline. Studies have shown that sermorelin can stimulate measurable increases in growth hormone output in appropriate patient populations when administered via injection. The clinical rationale for its use exists.

What the research does not support: sermorelin as a general anti-aging treatment, as a performance enhancement tool for individuals with normal growth hormone levels, or as a guaranteed approach to improving body composition or energy in non-deficient adults. Sermorelin is not approved for these applications. No legitimate medical provider can guarantee outcomes from peptide therapy, and claims that sermorelin will produce specific effects on body composition, energy, or longevity in unselected patient populations exceed what peer-reviewed evidence supports.

The more difficult research question applies specifically to oral sermorelin. Peptides face significant challenges with oral bioavailability. The gastrointestinal tract contains proteases that degrade peptides before they reach systemic circulation, which is why most established peptide therapies use injectable delivery routes. The clinical evidence base for oral sermorelin formulations — including any sublingual or swallowed tablet format — is substantially more limited than for injectable sermorelin. This is not unique to MadeMed; it applies to oral peptide delivery across the telehealth market.

How MadeMed's Peptide Therapy Programs Are Structured

MadeMed offers sermorelin in both injectable and oral formats. The enrollment process follows the same telehealth model as the platform's GLP-1 programs: prospective patients complete an online medical intake, which is reviewed by a licensed clinician affiliated with Xpedicare, LLC. Prescribing is at the clinician's sole discretion. There is no guarantee that a prescription will be issued. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner, and shipped directly to the patient.

Sermorelin is typically administered at night, before sleep, because growth hormone secretion follows a circadian pattern with peak release during slow-wave sleep. Injectable sermorelin is administered subcutaneously — the same delivery method as injectable GLP-1 medications. Dosing and titration protocols are determined by the prescribing clinician based on individual patient assessment.

The subscription and billing structure for peptide therapy follows the same terms as MadeMed's other programs: recurring billing (30 or 90 day cycles), no prorated refunds, cancellation available via email or through the patient portal. Review the full Terms of Use at mademed.com before enrolling.

NAD+ Therapy: MadeMed's Other Longevity Category

MadeMed also offers NAD+ (nicotinamide adenine dinucleotide) therapy in injectable and nasal spray formats, priced up to $269 per month for the nasal spray at higher tiers. NAD+ is a coenzyme involved in cellular energy metabolism, and there is ongoing research interest in NAD+ precursors and direct NAD+ supplementation in the context of aging and metabolic health. As with sermorelin, the clinical evidence base for NAD+ therapy in healthy, non-deficient adults — and specifically for injectable and nasal spray formats at the doses used in telehealth programs — is substantially more limited than the marketing language around “longevity medicine” typically conveys. Discuss the evidence with your provider before starting any NAD+ program.

Who Peptide Therapy May Be Appropriate For

Sermorelin may be clinically appropriate for adults with documented growth hormone deficiency confirmed through lab testing, or for individuals where a licensed clinician determines it may be medically indicated after reviewing individual health history and goals. It is not a general wellness product and is not appropriate as a self-directed supplement or as a substitute for lifestyle interventions in growth-hormone-sufficient adults. Clinical evaluation before prescribing — including a thorough health history review — is the baseline standard for any responsible peptide therapy program.

If you're researching MadeMed primarily for weight loss support, the GLP-1 programs are the more evidence-anchored starting point. See our full MadeMed platform review for a complete breakdown of all programs, pricing, and what to verify before enrolling. For comparison with other telehealth platforms that offer peptide therapy alongside GLP-1 programs, see our review of TeleHealth Med, which covers a comparable care model.

What to Ask Your Provider Before Starting Sermorelin

Has your growth hormone status been evaluated through lab testing? What IGF-1 levels would indicate you're a candidate for sermorelin therapy? Will you receive a baseline lab assessment before prescribing? What does dose titration look like and how is response monitored over time? What is the compounding pharmacy's accreditation status and quality assurance process for the specific formulation? How long is a reasonable trial period before evaluating whether the therapy is producing any measurable response? Are there contraindications given your current medications or health history?

These are not difficult questions — they're the baseline clinical due diligence any responsible provider should be prepared to answer. A platform or provider that can't or won't engage with them is a signal to seek a different clinical relationship.

Frequently Asked Questions

What is sermorelin and how does it work?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release growth hormone through the body's natural regulatory pathways, rather than introducing exogenous growth hormone directly. It requires a licensed provider evaluation and is not approved for anti-aging or general wellness use. Clinical applications have included evaluation for growth hormone deficiency under physician supervision.

Is MadeMed's sermorelin FDA-approved?

Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency, but that approval was voluntarily withdrawn by the manufacturer. Sermorelin prescribed through telehealth platforms today is typically compounded, meaning it is not an FDA-approved finished drug product and has not been evaluated by the FDA for safety or efficacy in its compounded form.

What is the difference between injectable and oral sermorelin at MadeMed?

MadeMed offers both injectable and oral sermorelin formats. Injectable sermorelin is administered subcutaneously and is the more established delivery route in clinical literature. Oral peptide delivery faces significant bioavailability challenges due to degradation in the gastrointestinal tract. The clinical evidence base for oral sermorelin formulations is substantially more limited than for injectable formats. Discuss which format is appropriate for your situation with a licensed provider before starting.

Important: Compounded GLP-1 medications discussed in this article are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational and informational purposes only. All prescription decisions are made by licensed healthcare providers. Consult your provider before starting any prescription medication.

One of the most common questions prospective patients ask about GLP-1 telehealth programs right now is whether the oral format actually works — and whether it's worth choosing over an injectable. MadeMed offers both, starting at $99 per month for oral semaglutide and also offering injectable semaglutide and both oral and injectable tirzepatide. This article breaks down what the research actually supports, what “oral semaglutide” means in the telehealth context, and how to think about the format decision from an evidence standpoint.

What “Oral Semaglutide” Actually Means in 2026

The term “oral GLP-1” covers at least four meaningfully different things in the current market, and conflating them produces bad decisions. Understanding the distinctions is the most important thing this article can offer.

FDA-approved oral semaglutide includes two products: Rybelsus, a daily swallowed tablet approved for type 2 diabetes management, and the oral Wegovy formulation that launched in late 2025 for weight management. Both have completed phase 3 clinical trial programs evaluating their efficacy, safety, and pharmacokinetics as finished drug products. They require specific administration conditions — typically an empty stomach, small amount of water, and a waiting period before eating — because oral bioavailability of semaglutide is inherently challenging due to its peptide structure and susceptibility to gastric degradation.

Compounded sublingual semaglutide — the format available through MadeMed and most other GLP-1 telehealth platforms — is a separate category. These are compounding pharmacy formulations that dissolve under the tongue rather than being swallowed. The mechanism bypasses initial gastric transit by relying on sublingual absorption through the mucous membranes. This is a pharmacologically coherent delivery route. However, compounded sublingual semaglutide has not been evaluated in equivalent phase 3 human clinical trials. The bioavailability, pharmacokinetic profile, and clinical outcomes of these formulations cannot be assumed to match those of either FDA-approved injectable semaglutide or FDA-approved oral semaglutide based on preclinical or theoretical arguments alone.

This isn't a reason to dismiss the format — it's a reason to understand what you're actually choosing. For a detailed review of how MadeMed structures its programs across all GLP-1 formats, see our full MadeMed platform review.

What the Injectable Evidence Base Establishes

Injectable semaglutide has the strongest and most established evidence base of any semaglutide formulation. The STEP trial program, published in peer-reviewed literature including the New England Journal of Medicine, studied once-weekly subcutaneous semaglutide at 2.4mg in adults with obesity combined with lifestyle intervention. The STEP 1 trial found clinically meaningful average body weight reduction in the treatment group versus placebo after 68 weeks. These are the trials that established the clinical rationale for GLP-1 therapy in weight management — and they used injectable, FDA-approved branded semaglutide under controlled trial conditions.

Compounded injectable semaglutide — the format also available through MadeMed — uses the same active ingredient (semaglutide) administered the same way (subcutaneous injection), but is a compounded formulation rather than an FDA-approved finished drug. The pharmacological mechanism is the same, but the regulatory status, quality control standards, and evidence basis for the specific compounded formulation differ. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality control before they are dispensed.

The Oral Semaglutide Clinical Picture: What Phase 3 Data Shows for FDA-Approved Formats

The oral Wegovy clinical program (OASIS trials) evaluated swallowed oral semaglutide at 50mg once daily in adults with obesity. Published results demonstrated meaningful weight reduction compared to placebo, though average weight loss figures were somewhat lower than those observed in the injectable STEP trials. These results establish proof of concept for oral semaglutide as a clinically effective approach — but again, these are trials of an FDA-approved finished drug product, not of compounded sublingual tablets.

The mechanistic argument for sublingual absorption is that it bypasses the gastric degradation challenge that makes oral peptide delivery difficult. Whether compounded sublingual semaglutide achieves clinically meaningful systemic exposure in practice — and at what doses — is not established by published phase 3 human trial data as of this writing. This is a genuine evidence gap, not a disqualifying flaw. Clinicians prescribe medications through compounding when the individual patient's needs support it. But patients deserve to know that the “oral semaglutide” available through telehealth platforms is not the same product, and does not have the same evidence base, as the oral Wegovy pill that launched in late 2025.

How MadeMed's Oral Semaglutide Pricing Compares to the Market

At a published starting price of $99 per month, MadeMed's oral semaglutide sits at the lower end of the compounded telehealth market for this format. For context, oral semaglutide sublingual tablets from other platforms are priced higher: the SynergyRx oral dissolving tablet program starts at $299 per month for semaglutide per publicly available information, while programs reviewed on this site, including FuturHealth and Remote Pharmacy, structure their pricing differently, with injectable-focused programs in comparable ranges.

The key pricing consideration that every prospective patient should apply: compare total cost at maintenance dose, not starting price. GLP-1 programs titrate upward over months. The $99 entry point applies to the lowest starting dose of oral semaglutide — the dose at which most clinical protocols begin before gradually increasing. As dose increases, price increases. The monthly cost at a therapeutic maintenance dose will be higher than the published starting price. Verify the full pricing tier structure directly on mademed.com before enrolling.

For the FDA-approved oral alternative: Novo Nordisk has published self-pay pricing for oral Wegovy at $149 per month for certain dose tiers through its manufacturer direct program. For patients who qualify and prefer an FDA-approved finished drug, the price differential between compounded sublingual semaglutide and the approved oral pill has narrowed significantly in 2026. This is a conversation to have with your prescribing clinician — not a decision to make based on cost alone, since eligibility, insurance, and individual medical history all factor in.

How to Think About the Format Decision

The right format — oral or injectable — is a clinical decision, not a marketing decision. A few questions worth discussing with your provider: Do you have any medical reason to avoid subcutaneous injections? Does your state's prescribing regulations or the platform's clinical protocols affect which formats are available to you? Is there a compounded tirzepatide option worth considering if semaglutide isn't the right fit? Are you looking for an FDA-approved finished drug product specifically, or are you open to a compounded formulation under medical supervision?

MadeMed offers the flexibility of both formats across two GLP-1 molecules (semaglutide and tirzepatide), which is a genuine differentiator compared to platforms that offer only one format or one molecule. Whether that flexibility translates to better outcomes for any individual patient is a question for their licensed clinician.

Frequently Asked Questions

Is oral semaglutide as effective as injectable semaglutide?

FDA-approved oral semaglutide (Rybelsus and oral Wegovy) has been studied in clinical trials and demonstrates meaningful weight reduction, though phase 3 trial data generally shows somewhat less average weight loss compared to injectable semaglutide at equivalent doses. Compounded sublingual semaglutide tablets — the format available through most telehealth platforms — have not been evaluated in equivalent phase 3 human trials. The bioavailability and clinical outcomes of compounded sublingual formats cannot be assumed to be equivalent to either FDA-approved injectable or FDA-approved oral semaglutide products.

Why is MadeMed's oral semaglutide priced lower than competitors?

MadeMed's published starting price for oral semaglutide ($99/month at the lowest dose) positions it at the lower end of the compounded telehealth market. Pricing differences between telehealth platforms reflect differences in pharmacy sourcing, bundled services, dose tier structures, and membership models. Lower starting price does not always reflect lower total cost at maintenance dose. Prospective patients should compare total monthly cost at their expected therapeutic dose, not just entry-level pricing.

What is the difference between compounded sublingual semaglutide and oral Wegovy?

Oral Wegovy is an FDA-approved finished drug product that has completed phase 3 clinical trials evaluating its safety, efficacy, and bioavailability as a swallowed tablet. Compounded sublingual semaglutide — the format available through telehealth platforms including MadeMed — is a compounding pharmacy formulation that dissolves under the tongue. It uses semaglutide as an active ingredient but is not FDA-approved and has not been evaluated in equivalent human clinical trials. The two formats have different regulatory statuses and different evidence bases.